ClinicalTrials.gg
CompletedNCT03626142Updated Oct 28, 2026

Assessing the Effectiveness of Psychiatric Interventions on the Inpatient Unit

An observational study in Depressive Symptoms and Suicidal Ideation, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Stanford University · Observational

How we know

Updated Oct 28, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
12
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Depression by Stanford University — 15 open to participants now, 17 under way, none of them phase 3. Depression · Stanford University.

Enrollment
12th of 12
12 · median 87
Started
2018
with 3 others
Observational
12 of 77
none open now
Registered
41st of 77
by date

Among the 77 studies in Depression by Stanford University, this one is the 12th largest by enrollment of the 12 observational ones that give a count, is one of 4 that started in 2018, is one of 12 observational ones, and was the 41st registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

15 of the 77 studies in Depression by Stanford University are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Depression by Stanford University, or all of them as a file.
02

Study summary

This study will monitor the symptoms of patients who have received an intervention on the psychiatric inpatient unit at Stanford hospital up to 6 months after they have received the intervention. Additionally, the acceptability and feasibility of interventions will be assessed using clinician and patient questionnaires.

Read the detailed description

Once patients have been discharged from hospital they will be contacted weekly for 4 weeks and then every 2 weeks until 6 months post-intervention in order to monitor their symptoms. Participants will be followed up until the end of the study (6 months after the intervention) or until they no longer meet responder criteria (MADRS score>50% of score before they received the intervention) During the follow-ups for the first 8 weeks, the following assessments will be conducted: Montgomery-Åsberg Depression Rating Scale (MADRS) Scale of suicidal ideation (SSI) Hamilton depression rating scale (HAMD-6) Young Mania Rating Scale (YMRS) Pittsburgh insomnia rating scale (PIRS-20) Quick inventory of depressive symptomatology (QIDS) Immediate Mood Scaler (IMS-12) Beck Depression Inventory (BDI-II) C-SSRS self-report short version

Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) will be collected at one month post-intervention.

If the participant has a psychiatric diagnosis(/es) other than MDD, questionnaires measuring the symptoms associated with the participant's other psychiatric diagnosis/(es) will also be administered.

Follow-up assessments from 10-24 weeks will include:

MADRS SSI BDI-II C-SSRS self-report short version

If the participant has a psychiatric diagnosis other than MDD, questionnaires measuring the symptoms associated with the participant's other psychiatric diagnosis/(es) will also be administered.

The questionnaires that will be used to assess symptoms associated with primary psychiatric diagnoses are:

  • Bipolar disorder: YMRS
  • Schizoaffective disorder/ Schizophrenia/Schizophreniform disorder: positive and negative symptom scale (PANSS) and the Calgary Depression Scale for Schizophrenia (CDSS)
  • Alcohol use disorder: Alcohol craving questionnaire self-report (ACQ-SR) and obsessive compulsive drinking scale (OCDS)
  • Drug use disorders: Modified versions of the alcohol scales to make these relevant to the particular drug of abuse.
  • Anorexia Nervosa: Yale-Brown-Cornell Eating Disorder Scale [YBC-EDS], Eating disorder examination questionnaire (EDE-Q)
  • Bulimia Nervosa: Yale-Brown-Cornell Eating Disorder Scale [YBC-EDS], Eating disorder examination questionnaire (EDE-Q)
  • Binge eating disorder: Young-Brown Obsessive Compulsive Scale Modified for Binge Eating [YBOCS-BE]
  • OCD: Obsessive compulsive inventory (OCI) and Yale-Brown Obsessive Compulsive Scale (YBOCS)
  • PTSD: Post-traumatic Stress Disorder Checklist-Civilian Version [PCL-C]
  • Generalized anxiety disorder: Generalized Anxiety Disorder 7-item (GAD-7) scale
  • Chronic pain: Numeric Rating Scale (NRS) for Chronic Pain
  • Panic Disorder: Panic Disorder Severity Scale (PDSS)
  • Somatoform Disorders: The Somatic Symptom Scale (SSS-8)
  • Impulse Control disorders: Massachusetts General Hospital Hairpulling Scale (This questionnaire will be adapted depending on the urges the patient cannot control e.g. compulsive picking) BPD: The Borderline Evaluation of Severity Over Time (BEST)

At all time points, information regarding medication changes and other psychiatric treatments will be collected.

03

Conditions studied

  • Depressive Symptoms
  • Suicidal Ideation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted to the psychiatric unit at Stanford University displaying depressive symptoms or suicidal ideation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received an intervention on the psychiatric inpatient unit at Stanford Hospital aimed at treating a major depressive episode or suicidal ideation

Exclusion criteria

Exclusion Criteria:

-None

05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
12 participants (actual)
Patient registry
No

Groups and cohorts

  • Left DLPFC aTBS stimulation

    Patients who have received accelerated theta burst stimulation delivered to the left dorsolateral prefrontal cortex on the inpatient unit at Stanford

  • ACC aTBS stimulation

    Patients who have received accelerated theta burst stimulation delivered to the anterior cingulate cortex on the inpatient unit at Stanford

  • ECT

    Patients who have received ECT on the inpatient unit at Stanford

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    This is a ten-item clinician rated questionnaire in which the clinician rates each item from 0-6. Scores of 6 indicate more severe depressive symptoms. Total scores are between 0 and 60 with scores \>35 indicating severe depression. Response is defined as a 50% reduction or greater in MADRS score compared to baseline. Remission is defined as a MADRS score of \<10.

    Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 24 weeks post-intervention

Secondary outcomes

  1. Scale for Suicide Ideation (SSI)

    Clinical assessment measuring suicidal thoughts \& behaviors

    Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 24 weeks post-intervention

  2. Beck Depression Inventory II (BDI-II)

    The Beck Depression Inventory (BDI-II) is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression. BDI-II items are rated on a 4-point scale ranging from 0 to 3 based on severity of each item. The maximum total score is 63. Scores: 0-13= minimal depression, 14-19=mild depression, 20-28=moderate depression, 29-63=severe depression

    Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 24 weeks post-intervention

  3. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Self-report questionnaire identifying the presence or absence of six suicidal thoughts or behaviors in the past month or since the last visit. Each 'yes' answer is scored as 1, meaning the maximum total score is 6. The scale identifies specific behaviors which may be indicative of a person's intent to complete suicide. An person exhibiting even a single behavior identified by the scale was 8 to 10 times more likely to complete suicide.

    Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 24 weeks post-intervention

  4. Young Mania Rating Scale (YMRS)

    11-item multiple choice clinician-rated questionnaire. Each question is rated from 0 to 4 with 4

    Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.

  5. Pittsburgh Insomnia Rating Scale (PIRS-20)

    Self-report insomnia rating scale

    Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.

  6. Hamilton Rating Scale for Depression Six Item (HAMD-6)

    Response is defined as a 50% reduction or greater in HAMD-6 score compared to baseline. HAMD-6 is a 6-item clinical assessment measuring depressive symptoms (scores range from 0-24 with scores of 5 or more indicating clinical levels of depression). The number of weeks in which HAMD-6 scores are lower than 50% of baseline will be calculated to provide a measure of duration of response.

    Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.

  7. Quick Inventory Depressive Symptomatology (QIDS)

    Self-report measure of depressive symptoms

    Time frame: Weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.

  8. Immediate Mood Scaler (IMS-12)

    12-item self-report questionnaire used to measure current mood

    Time frame: weekly for first 4 weeks, followed by bi-weekly up until 8 weeks post-intervention.

  9. Number of hospital re-admissions and service use

    The number of times patients are re-admitted to hospital and used psychiatric services since the last assessment will be recorded

    Time frame: Bi-weekly up until 24 weeks post-intervention

07

Study locations

1 site
  • Stanford Hospital
    Palo Alto, California 94305, United States
08

References and documents

Publications

  • Kelly MS, Oliveira-Maia AJ, Bernstein M, Stern AP, Press DZ, Pascual-Leone A, Boes AD. Initial Response to Transcranial Magnetic Stimulation Treatment for Depression Predicts Subsequent Response. J Neuropsychiatry Clin Neurosci. 2017 Spring;29(2):179-182. doi: 10.1176/appi.neuropsych.16100181. Epub 2016 Nov 30. PubMed 27899052 ↗
  • Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ. Response of depression to electroconvulsive therapy: a meta-analysis of clinical predictors. J Clin Psychiatry. 2015 Oct;76(10):1374-84. doi: 10.4088/JCP.14r09528. PubMed 26528644 ↗
  • Berggren A, Gustafson L, Hoglund P, Johanson A. A long-term follow-up of clinical response and regional cerebral blood flow changes in depressed patients treated with ECT. J Affect Disord. 2014;167:235-43. doi: 10.1016/j.jad.2014.06.005. Epub 2014 Jun 12. PubMed 24997226 ↗
  • Murrough JW, Perez AM, Pillemer S, Stern J, Parides MK, aan het Rot M, Collins KA, Mathew SJ, Charney DS, Iosifescu DV. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry. 2013 Aug 15;74(4):250-6. doi: 10.1016/j.biopsych.2012.06.022. Epub 2012 Jul 27. PubMed 22840761 ↗
  • Dell'osso B, D'Urso N, Castellano F, Ciabatti M, Altamura AC. Long-term efficacy after acute augmentative repetitive transcranial magnetic stimulation in bipolar depression: a 1-year follow-up study. J ECT. 2011 Jun;27(2):141-4. doi: 10.1097/YCT.0b013e3181f66601. PubMed 20966770 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jul 2018 to primary completion in Apr 2023, 56 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: primary completion Dec 2024 → Apr 2023 and completion Dec 2025 → Apr 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2018
First posted
Aug 10, 2018
StartActual
Jul 9, 2018
Primary completionActual
Apr 4, 2023was Dec 2024
CompletionActual
Apr 4, 2023was Dec 2025
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Completed
changed Oct 28, 2026
Primary completion
Dec 1, 2024→Apr 4, 2023 (actual)
Oct 28, 2026
Study completion
Dec 1, 2025→Apr 4, 2023 (actual)
Oct 28, 2026
Enrollment
200 (estimated)→12 (actual)
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Enrolling by invitation→Completed
    Primary completion Dec 1, 2024→Apr 4, 2023 (now actual)
    Study completion Dec 1, 2025→Apr 4, 2023 (now actual)
    Enrollment 200 (estimated)→12 (actual)
    + 3 other changes: verification date, responsible party and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT03626142
Responsible party
Sponsor
First posted
Aug 10, 2018
Start date
Jul 9, 2018
Primary completion
Apr 4, 2023
Completion
Apr 4, 2023
Last update
Oct 28, 2026

Study contacts

Nolan Williams, MD
principal investigator · Stanford University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion